List of Progress in Hematology "Review Series" 2013-2014
***2014***
Immunotherapy for hematological malignancies (Edited by Norimitsu Kadowaki)
1. Bocchia M, Defina M, Aprile L, Sicuranza A. Peptide vaccines for hematological malignancies: a missed promise? Int. J. Hematol.
99:107-116, 2014
2. Kitawaki K. DC-based immunotherapy for hematological malignancies. Int. J. Hematol. 99:117-122, 2014
3. Fujiwara H. Adoptive T-cell therapy for hematological malignancies using T cells gene-modified to express tumor antigen-specific
receptors. Int. J. Hematol. 99:123-131, 2014
4. Turtle CJ. Chimeric antigen receptor modified T cell therapy for B cell malignancies. Int. J. Hematol. 99:132-140, 2014
Peripheral T cell lymphoma (Edited by Masaki Yasukawa)
1. Piccaluga PP, Tabanelli V, Pileri SA. Molecular genetics of peripheral T-cell lymphomas. Int. J. Hematol. 99:219-226, 2014
2. Park S, Ko YH. Peripheral T cell lymphoma in Asia. Int. J. Hematol. 99:227-239, 2014
3. Ohshima K, Niino D, Karube K. Microenvironment of adult T-cell leukemia/lymphoma-associated nodal lesions. Int. J. Hematol.
99:240-248, 2014
4. Intlekofer AM, Younes A. From empiric to mechanism-based therapy for peripheral T cell lymphoma. Int. J. Hematol. 99:249-262,
2014
Recent Progress in Gene Therapy (Edited by Keiya Ozawa)
1. Davila ML, Bouhassira DCG, Park JH, Curran KJ, Smith EL, Pegram HJ, Brentjens R. Chimeric antigen receptors for the adoptive
T cell therapy of hematologic malignancies. Int. J. Hematol. 99:361-371, 2014
2. Patel N, Reiss U, Davidoff AM, Nathwani AC. Progress towards gene therapy for haemophilia B. Int. J. Hematol. 99:372-376, 2014
3. Uchibori R, Tsukahara T, Ohmine K, Ozawa K. Cancer gene therapy using mesenchymal stem cells. Int. J. Hematol. 99:377-382,
2014
4. Candotti F. Gene transfer into hematopoietic stem cells as treatment for primary immunodeficiency diseases. Int. J. Hematol.
99:383-392, 2014
Noncoding RNA in hematopoietic system (Edited by Ai Kotani)
1. Alvarez-Dominguez JR, Hu W, Gromatzky AA, Lodish HF. Long noncoding RNAs during normal and malignant hematopoiesis. Int.
J. Hematol. 99:531-541, 2014
2. Ikeda S, Tagawa H. Dysregulation of microRNAs and their association in the pathogenesis of T-cell lymphoma/leukemias. Int. J.
Hematol. 99:542-552, 2014
3. Okuyama K, Ogata J, Yamakawa N, Chanda B, Kotani A. Small RNA as a regulator of hematopoietic development, immune
response in infection and tumorigenesis. Int. J. Hematol. 99:553-560, 2014
Hematopoietic regulators in the marrow: new players in inter-organ communication (Edited by Yoshio Katayama)
1. Asada N, Katayama Y. Regulation of hematopoiesis in endosteal microenvironments. Int. J. Hematol. 99:679-684, 2014
2. Casanova-Acebes M, A-González N, Weiss LA, Hidalgo A. Innate immune cells as homeostatic regulators of the hematopoietic niche.
Int. J. Hematol. 99:685-694, 2014
3. Yamazaki S, Nakauchi H. Bone marrow Schwann cells induce hematopoietic stem cell hibernation. Int. J. Hematol. 99:695-698, 2014
4. Kunisaki Y, Frenette PS. Influences of vascular niches on hematopoietic stem cell fate. Int. J. Hematol. 99:699-705, 2014
Basic and Clinical Updates in Acute Promyelocytic Leukemia (Edited by Norio Komatsu)
1. Nakahara F, Weiss CN, Ito K. The role of PML in hematopoietic and leukemic stem cell maintenance. Int. J. Hematol. 100:18-26,
2014
2. Ikezoe T. Pathogenesis of disseminated intravascular coagulation in patients with acute promyelocytic leukemia, and its treatment
using recombinant human soluble thrombomodulin. Int. J. Hematol. 100:27-37, 2014
3. Li J, Zhu H, Hu J, Mi J, Chen S, Chen Z, Wang Z. Progress in the treatment of acute promyelocytic leukemia: optimization and
obstruction. Int. J. Hematol. 100:38-50, 2014
Epigenetic regulation of lymphopoiesis (Edited by Takafumi Yokota)
1. Yoshida T, Georgopoulos K. Ikaros fingers on lymphocyte differentiation. Int. J. Hematol. 100:220-229, 2014
2. Shimazaki N, Lieber MR. Histone methylation and V(D)J recombination. Int. J. Hematol. 100: 230-237, 2014
3. Yokota T, Kanakura Y. Role of tissue-specific AT-rich DNA sequence-binding proteins in lymphocyte differentiation. Int. J. Hematol.
100:238-245, 2014
4. Johanson TM, Skinner JPJ, Kumar A, ZhanY, Lew AM, Chong MMW. The role of microRNAs in lymphopoiesis. Int. J. Hematol.
100:246-253, 2014
Hematopoietic Stem Cell Aging and Chronic Lymphocytic Leukemia Pathogenesis (Edited by Toshio Suda)
1. Nakamura-Ishizu A, Suda T. Aging of the hematopoietic stem cells niche. Int. J. Hematol. 100:317-325, 2014
2. Oshima M, Iwama A. Epigenetics of hematopoietic stem cell aging and disease Int. J. Hematol. 100:326-334, 2014
3. Kikushige Y, Miyamoto T. Hematopoietic stem cell aging and chronic lymphocytic leukemia pathogenesis Int. J. Hematol.
100:335-340, 2014
***2013***
Recent advances in genetic basis of childhood hemato-oncological diseases (Edited by Shuki Mizutani)
5. Urayama KY, Chokkalingam AP, Manabe A, Mizutani S. Current evidence for an inherited genetic basis of childhood acute
lymphoblastic leukemia. Int. J. Hematol. 97:3-19, 2013
6. Sakaguchi H, Nakanishi K, Kojima S. Inherited bone marrow failure syndromes in 2012. Int. J. Hematol. 97:20-29, 2013
7. Aoki Y, Matsubara Y. Ras/MAPK syndromes and childhood hemato-oncological diseases. Int. J. Hematol. 97:30-36, 2013
8. Mizutani S, Takagi M. XCIND as a genetic disease of X-irradiation hypersensitivity and cancer Susceptibility. Int. J. Hematol.
97:37-42, 2013
Genetic and epigenetic alterations in hematopoietic malignancies (Edited by Toshio Kitamura)
1.
Naoe T, Kiyoi H. Gene mutations of acute myeloid leukemia in the genome era. Int. J. Hematol. 97:165-174, 2013
2.
Yamazaki J, Issa J-P.J. Epigenetic aspects of MDS and its molecular targeted therapy. Int. J. Hematol. 97:175-182, 2013
3.
Milosevic JD, Kralovics R. Genetic and epigenetic alterations of myeloproliferative disorders Int. J. Hematol. 97:183-197, 2013
4.
Vu LP., Luciani L, Nimer SD. Histone-modifying enzymes: their role in the pathogenesis of acute leukemia and their therapeutic
potential Int. J. Hematol. 97:198-209, 2013
Basic and Clinical Updates in Multiple Myeloma (Edited by Masahiro Kizaki)
1. Hosen N, Multiple myeloma-initiating cells. Int. J. Hematol. 97:306-312, 2013
2. Chesi M, Bergsagel PL. Molecular pathogenesis of multiple myeloma: basic and clinical updates. Int. J. Hematol. 97:313-323, 2013
3. Hideshima T, Anderson KC. Histone deacetylase inhibitors in the treatment for multiple myeloma Int. J. Hematol. 97:324-322, 2013
4. Watanabe R, Tokuhira M, Kizaki M. Current approaches for the treatment of multiple myeloma. Int. J. Hematol. 97:333-344, 2013
Advances in the Management of Acquired Aplastic Anemia (AA) (Edited by Shinji Nakao)
1. Scheinberg P, Prognostic value of telomere attrition in patients with aplastic anemia. Int. J. Hematol. 97: 553-557, 2013
2. Yamazaki H, Nakao S, Border between aplastic anemia and myelodysplastic syndrome. Int. J. Hematol. 97: 558-563, 2013
3. Shin SH, Lee JW, The optimal immunosuppressive therapy for aplastic anemia. Int. J. Hematol. 97: 564-572, 2013
4. Gandhi S, Kulasekararaj AG, Mufti GJ, Marsh JC. Allogeneic stem cell transplantation using alemtuzumab-containing regimens
in severe aplastic anemia. Int. J. Hematol. 97: 573-580, 2013
Efficacy and resistance of molecularly targeted therapy for myeloid malignancies (Edited by Hitoshi Kiyoi)
1.
Grunwald MR, Levis MJ, FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance. Int. J.
Hematol. 97: 683-694, 2013
2.
Bhagwat N, Levine RL, Koppikar P, Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms. Int. J.
Hematol.97: 695-702, 2013
3.
Takeshita A, Efficacy and resistance of gemtuzumab ozogamicin for acute myeloid leukemia. Int. J. Hematol. 97: 703-716, 2013
4. Tomita A, Kiyoi H, Naoe T, Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3) in
acute promyelocytic leukemia. Int. J. Hematol. 97: 717-725, 2013
Pathophysiology and management of thrombocytopenia: Possible clinical application of TPO receptor agonists (Edited by Yoshiaki
Tomiyama)
1.
Kuter DJ, The biology of thrombopoietin and thrombopoietin receptor agonists. Int. J. Hematol. 98: 10-23, 2013
2.
Kashiwagi H, Tomiyama Y, Pathophysiology and management of primary immune thrombocytopenia, Int. J. Hematol. 98:24-33,
2013
3.
Pecci A, Pathogenesis and management of inherited thrombocytopenias: rationale for the use of thrombopoietin-receptor agonists,
Int. J. Hematol. 98: 34-47, 2013
4.
Townsley DM, Desmond R, Dunbar CE, Young NS, Pathophysiology and management of thrombocytopenia in bone marrow failure:
possible clinical applications of TPO receptor agonists in aplastic anemia and myelodysplastic syndromes, Int. J. Hematol. 98: 48-55,
2013
New clinical and basic aspects of graft-versus-host disease (Edited by Akiyoshi Takami)
1.
Paczesny S, Raiker N, Brooks S, Mumaw C, Graft-versus-host disease biomarkers: omics and personalized medicine, Int. J. Hematol.
98: 275-292, 2013
2.
Maeda Y., Pathogenesis of graft-versus-host disease: innate immunity amplifying acute alloimmune responses, Int. J. Hematol. 98:
293-299, 2013
3.
Kanda J, Effect of HLA mismatch on acute graft-versus-host disease, Int. J. Hematol. 98: 300-308, 2013
4.
Takami A, The role of non-HLA gene polymorphisms in graft-versus-host disease, Int. J. Hematol. 98: 309-318, 2013
Leukemia Stem Cell (Edited by Koichi Akashi)
1.
Kikushige Y., Miyamoto T., TIM-3 as a novel therapeutic target for eradicating acute myelogenous leukemia stem cells, Int. J.
Hematol. 98: 627-633, 2013
2.
Ishikawa F., Modeling normal and malignant human hematopoiesis in vivo through newborn NSG xenotransplantation, Int. J.
Hematol. 98: 634-640, 2013
3.
Ito T., Stem cell maintenance and disease progression in chronic myeloid leukemia, Int. J. Hematol. 98: 641-647, 2013
4.
Chan S.M., Majeti R., Role of DNMT3A, TET2, and IDH1/2 mutations in pre-leukemic stem cells in acute myeloid leukemia, Int. J.
Hematol. 98: 648-657, 201398: 275-292, 2013